Tune Therapeutics, a biotech company which develops medicines through investigational epigenetics, has closed a series B financing round worth over $175 million. The round was led by New Enterprise Associates, Regeneron Ventures and Hevolution Foundation.

The financing will be used to fund the expansion of Tune’s current pipeline, including Tune-401,  the company’s first-in-class clinical candidate for the treatment of Hepatitis B (HBV) via gene silencing. The development of other genetic, cellular and regenerative therapies will also be supported by these funds.